Philadelphia, PA (Vocus) July 9, 2009
The relationship between migraine headaches in women and a significant reduction in breast cancer risk has been confirmed in a follow-up study to landmark research published last year. Results of this new study showed a 26 percent reduced risk of breast cancer among premenopausal and postmenopausal women with a clinical diagnosis of migraines.
The study appears in the July issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. Christopher I. Li, M.D., Ph.D., led the first-of-its-kind study linking migraines with breast cancer risk reduction, which was published in the same journal last November. Li is a breast-cancer epidemiologist and associate member of the Fred Hutchinson Cancer Research Center’s Public Health Sciences Division, in Seattle.
This time, Li and colleagues found that the risk reduction remained statistically similar regardless of a woman’s menopausal status, her age at migraine diagnosis, use of prescription migraine medications or whether she avoided known migraine “triggers” such as alcohol consumption, smoking and taking hormone replacement. These triggers are also well-established breast cancer risk factors.
Some key differences between this study and the initial one in which Li and colleagues discovered the link include:
What remains unknown is why migraines are associated with lower breast cancer risk.
“We know that migraines are definitely related to hormones and that’s why we started looking at this in the first place,” said Li. “We have different ideas about what may be going on but it’s unclear exactly what the biological mechanisms are.”
In the meantime, research on migraines and breast cancer continues. Li and colleagues are conducting a follow-up investigation among the women in the first study to determine the types, timing, intensity and severity of their migraines in hopes that the data may elicit additional clues.
Joanne F. Dorgan, Ph.D., M.P.H., an epidemiologist at Fox Chase Cancer Center in Philadelphia, said that non-steroidal anti-inflammatory drugs are frequently used to treat migraine and these drugs have been associated with lower breast cancer risk in some studies. Additional research is needed to clarify the effect of non-steroidal anti-inflammatory drugs use on the observed association between migraines and breast cancer.
“Estrogen and progesterone are neurosteroids, and investigations into neuroendocrine pathways in relationship to breast cancer risk might also prove to be fruitful,” said Dorgan, who is also an editorial board member of Cancer Epidemiology, Biomarkers & Prevention.
Subscribe to the Cancer Epidemiology, Biomarkers & Prevention
RSS feed.
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 28,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and nearly 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
###